ACM
REGN icon

Avalon Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Avalon Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-3,245
Closed -$1.21M – 48
2018
Q4 		$1.21M Sell
3,245
-1,264
-28% -$463K 1.29% 20
2018
Q3 		$1.82M Buy
+4,509
New +$1.72M 1.66% 21
2017
Q3 		– Sell
-2,319
Closed -$1.14M – 109
2017
Q2 		$1.14M Buy
+2,319
New +$1.01M 0.84% 44

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Avalon Capital Management's REGN Position: Q1 2019 in Review

Avalon Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2019, closing a stake of 3,245 shares — an estimated $1.21M sold.

Avalon Capital Management first reported a position in REGN in Q2 2017 and held it in 3 quarters. The position peaked at $1.82M in Q3 2018. 719 funds tracked by Wall St. Rank hold REGN as of Q1 2019.

  • Avalon Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Avalon Capital Management sold 3,245 Regeneron Pharmaceuticals shares in Q1 2019, an estimated $1.21M.
  • Avalon Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2017 and held it in 3 quarters.
  • Avalon Capital Management's Regeneron Pharmaceuticals position peaked at $1.82M in Q3 2018.
  • 719 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2019.

Based on Avalon Capital Management's 13F filing for Q1 2019, filed 12 Apr 2019.